Sales & Marketing News | pharmaphorum

News

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.

News

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

News

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

News

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.

News

MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.

News

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.